
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6253941/publications.pdf Version: 2024-02-01



CEDALD T NEDOM

#	Article	lF	CITATIONS
1	Exhausted-like CD8+ T cell phenotypes linked to C-peptide preservation in alefacept-treated T1D subjects. JCI Insight, 2021, 6, .	5.0	37
2	Uncovering Pathways to Personalized Therapies in Type 1 Diabetes. Diabetes, 2021, 70, 831-841.	0.6	20
3	Approaches to Establishing Tolerance in Immune Mediated Diseases. Frontiers in Immunology, 2021, 12, 744804.	4.8	7
4	Autoreactive T cell receptors with shared germline-like $\hat{i}\pm$ chains in type 1 diabetes. JCI Insight, 2021, 6, .	5.0	14
5	Beta cell-specific CD8+ T cells maintain stem cell memory-associated epigenetic programs during type 1 diabetes. Nature Immunology, 2020, 21, 578-587.	14.5	63
6	Discriminative T cell recognition of cross-reactive islet-antigens is associated with HLA-DQ8 transdimer–mediated autoimmune diabetes. Science Advances, 2019, 5, eaaw9336.	10.3	15
7	Abatacept Targets T Follicular Helper and Regulatory T Cells, Disrupting Molecular Pathways That Regulate Their Proliferation and Maintenance. Journal of Immunology, 2019, 202, 1373-1382.	0.8	46
8	A composite immune signature parallels disease progression across T1D subjects. JCl Insight, 2019, 4, .	5.0	15
9	Autoreactive CD8+ T cell exhaustion distinguishes subjects with slow type 1 diabetes progression. Journal of Clinical Investigation, 2019, 130, 480-490.	8.2	99
10	Synchronous immune alterations mirror clinical response during allergen immunotherapy. Journal of Allergy and Clinical Immunology, 2018, 141, 1750-1760.e1.	2.9	61
11	Academic, Foundation, and Industry Collaboration in Finding New Therapies. New England Journal of Medicine, 2017, 376, 1762-1769.	27.0	57
12	Antigen-Specific T Cell Analysis Reveals That Active Immune Responses to β Cell Antigens Are Focused on a Unique Set of Epitopes. Journal of Immunology, 2017, 199, 91-96.	0.8	20
13	Single-Cell RNA Sequencing Reveals Expanded Clones of Islet Antigen-Reactive CD4+ T Cells in Peripheral Blood of Subjects with Type 1 Diabetes. Journal of Immunology, 2017, 199, 323-335.	0.8	62
14	Looking behind the data curtain. Cellular Immunology, 2017, 319, 1-2.	3.0	1
15	Rebranding asymptomatic type 1 diabetes: the case for autoimmune beta cell disorder as a pathological and diagnostic entity. Diabetologia, 2017, 60, 35-38.	6.3	28
16	A Contra Capture Protein Array Platform for Studying Post-translationally Modified (PTM) Auto-antigenomes. Molecular and Cellular Proteomics, 2016, 15, 2324-2337.	3.8	21
17	Genetically modified human <scp>CD</scp> 4 <sup>+</sup> T cells can be evaluated <i>inÂvivo</i> without lethal graftâ€versusâ€host disease. Immunology, 2016, 148, 339-351.	4.4	9
18	Correlation Among Hypoglycemia, Glycemic Variability, and C-Peptide Preservation After Alefacept Therapy in Patients with Type 1 Diabetes Mellitus: Analysis of Data from the Immune Tolerance Network T1DAL Trial. Clinical Therapeutics, 2016, 38, 1327-1339.	2.5	23

#	Article	IF	CITATIONS
19	Clinical trial data access: Opening doors with TrialShare. Journal of Allergy and Clinical Immunology, 2016, 138, 724-726.	2.9	12
20	Partial exhaustion of CD8 T cells and clinical response to teplizumab in new-onset type 1 diabetes. Science Immunology, 2016, 1, .	11.9	169
21	A Preclinical Consortium Approach for Assessing the Efficacy of Combined Anti-CD3 Plus IL-1 Blockade in Reversing New-Onset Autoimmune Diabetes in NOD Mice. Diabetes, 2016, 65, 1310-1316.	0.6	34
22	Obstacles and opportunities for targeting the effector T cell response in type 1 diabetes. Journal of Autoimmunity, 2016, 71, 44-50.	6.5	18
23	Adult-onset type 1 diabetes patients display decreased IGRP-specific Tr1 cells in blood. Clinical Immunology, 2015, 161, 270-277.	3.2	23
24	Biomarkers for antigen immunotherapy in allergy and type 1 diabetes. Clinical Immunology, 2015, 161, 44-50.	3.2	12
25	Functional inflammatory profiles distinguish myelin-reactive T cells from patients with multiple sclerosis. Science Translational Medicine, 2015, 7, 287ra74.	12.4	246
26	Alefacept provides sustained clinical and immunological effects in new-onset type 1 diabetes patients. Journal of Clinical Investigation, 2015, 125, 3285-3296.	8.2	228
27	Avidity-Dependent Programming of Autoreactive T Cells in T1D. PLoS ONE, 2014, 9, e98074.	2.5	5
28	Restoring the balance: immunotherapeutic combinations for autoimmune disease. DMM Disease Models and Mechanisms, 2014, 7, 503-513.	2.4	84
29	Low HERV-K(C4) Copy Number Is Associated With Type 1 Diabetes. Diabetes, 2014, 63, 1789-1795.	0.6	34
30	Targeting of memory T cells with alefacept in new-onset type 1 diabetes (T1DAL study): 12 month results of a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Diabetes and Endocrinology,the, 2013, 1, 284-294.	11.4	169
31	Antigen-specific immunomodulation for type 1 diabetes by novel recombinant antibodies directed against diabetes-associates auto-reactive T cell epitope. Journal of Autoimmunity, 2013, 47, 83-93.	6.5	14
32	Anti-cytokine therapies in T1D: Concepts and strategies. Clinical Immunology, 2013, 149, 279-285.	3.2	56
33	Systems Scale Interactive Exploration Reveals Quantitative and Qualitative Differences in Response to Influenza and Pneumococcal Vaccines. Immunity, 2013, 38, 831-844.	14.3	284
34	IL-10 Induction from Implants Delivering Pancreatic Islets and Hyaluronan. Journal of Diabetes Research, 2013, 2013, 1-9.	2.3	6
35	Transient B-Cell Depletion with Anti-CD20 in Combination with Proinsulin DNA Vaccine or Oral Insulin: Immunologic Effects and Efficacy in NOD Mice. PLoS ONE, 2013, 8, e54712.	2.5	33
36	Self-reactive human CD4 T cell clones form unusual immunological synapses. Journal of Experimental Medicine, 2012, 209, 335-352.	8.5	77

#	Article	IF	CITATIONS
37	Reversal of Diabetes in Mice with a Bioengineered Islet Implant Incorporating a Type I Collagen Hydrogel and Sustained Release of Vascular Endothelial Growth Factor. Cell Transplantation, 2012, 21, 2099-2110.	2.5	36
38	Hyaluronan and versican in the control of human T-lymphocyte adhesion and migration. Matrix Biology, 2012, 31, 90-100.	3.6	126
39	A functional framework for interpretation of genetic associations in T1D. Current Opinion in Immunology, 2012, 24, 516-521.	5.5	9
40	MHC Class II Tetramers. Journal of Immunology, 2012, 188, 2477-2482.	0.8	105
41	Immune-Directed Therapy for Type 1 Diabetes at the Clinical Level: The Immune Tolerance Network (ITN) Experience. Review of Diabetic Studies, 2012, 9, 359-371.	1.3	15
42	Reversal of Diabetes in Mice with a Bioengineered Islet Implant Incorporating a Type I Collagen Hydrogel and Sustained Release of Vascular Endothelial Growth Factor. Cell Transplantation, 2012, , .	2.5	1
43	Challenges in the pursuit of immune tolerance. Immunological Reviews, 2011, 241, 49-62.	6.0	23
44	Common variants in P2RY11 are associated with narcolepsy. Nature Genetics, 2011, 43, 66-71.	21.4	215
45	Identification and functional characterization of T cells reactive to citrullinated vimentin in HLA-DRB1*0401-positive humanized mice and rheumatoid arthritis patients. Arthritis and Rheumatism, 2011, 63, 2873-2883.	6.7	128
46	ECM components guide IL-10 producing regulatory T-cell (TR1) induction from effector memory T-cell precursors. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 7938-7943.	7.1	122
47	Increased Frequencies of Myelin Oligodendrocyte Glycoprotein/MHC Class II-Binding CD4 Cells in Patients with Multiple Sclerosis. Journal of Immunology, 2011, 187, 1039-1046.	0.8	61
48	Investigating the Role of T-Cell Avidity and Killing Efficacy in Relation to Type 1 Diabetes Prediction. PLoS ONE, 2011, 6, e14796.	2.5	12
49	Characterizing T-Cell Autoimmunity. , 2011, , 53-68.		0
50	Insulin Gene VNTR Genotype Associates with Frequency and Phenotype of the Autoimmune Response to Proinsulin. Clinical Immunology, 2010, 135, S6-S7.	3.2	1
51	Short-term IL-1β blockade reduces monocyte CD11b integrin expression in an IL-8 dependent fashion in patients with type 1 diabetes. Clinical Immunology, 2010, 136, 170-173.	3.2	19
52	A functional <i>RANKL</i> polymorphism associated with younger age at onset of rheumatoid arthritis. Arthritis and Rheumatism, 2010, 62, 2864-2875.	6.7	35
53	Prediction and Pathogenesis in Type 1 Diabetes. Immunity, 2010, 32, 468-478.	14.3	270
54	Th1 cytokines promote T-cell binding to antigen-presenting cells via enhanced hyaluronan production and accumulation at the immune synapse. Cellular and Molecular Immunology, 2010, 7, 211-220.	10.5	65

#	Article	IF	CITATIONS
55	The Immune Tolerance Network at 10 years: tolerance research at the bedside. Nature Reviews Immunology, 2010, 10, 797-803.	22.7	55
56	Evidence for Molecular Mimicry between Human T Cell Epitopes in Rotavirus and Pancreatic Islet Autoantigens. Journal of Immunology, 2010, 184, 2204-2210.	0.8	100
57	Recurrence of Type 1 Diabetes After Simultaneous Pancreas-Kidney Transplantation, Despite Immunosuppression, Is Associated With Autoantibodies and Pathogenic Autoreactive CD4 T-Cells. Diabetes, 2010, 59, 947-957.	0.6	210
58	On-Chip Activation and Subsequent Detection of Individual Antigen-Specific T Cells. Analytical Chemistry, 2010, 82, 473-477.	6.5	32
59	The Toll-Like Receptor Signaling Molecule Myd88 Contributes to Pancreatic Beta-Cell Homeostasis in Response to Injury. PLoS ONE, 2009, 4, e5063.	2.5	39
60	Genetics of Type 1A Diabetes. New England Journal of Medicine, 2009, 360, 1646-1654.	27.0	437
61	Restricted Autoantigen Recognition Associated with Deletional and Adaptive Regulatory Mechanisms. Journal of Immunology, 2009, 183, 59-65.	0.8	19
62	Intact extracellular matrix and the maintenance of immune tolerance: high molecular weight hyaluronan promotes persistence of induced CD4+CD25+ regulatory T cells. Journal of Leukocyte Biology, 2009, 86, 567-572.	3.3	131
63	CD44 Costimulation Promotes FoxP3+ Regulatory T Cell Persistence and Function via Production of IL-2, IL-10, and TGF-β. Journal of Immunology, 2009, 183, 2232-2241.	0.8	134
64	F.69. Selection of Antigen Specific Autoreactive T Cells is Influenced by INS-VNTR Genotype. Clinical Immunology, 2009, 131, S112.	3.2	0
65	Changes in autoreactive T cell avidity during type 1 diabetes development. Clinical Immunology, 2009, 132, 312-320.	3.2	28
66	Functional isletâ€specific Treg can be generated from CD4 <sup>+</sup> CD25 <sup>â^'</sup> T cells of healthy and type 1 diabetic subjects. European Journal of Immunology, 2009, 39, 612-620.	2.9	44
67	Remodeling rodent models to mimic human type 1 diabetes. European Journal of Immunology, 2009, 39, 2049-2054.	2.9	29
68	Narcolepsy is strongly associated with the T-cell receptor alpha locus. Nature Genetics, 2009, 41, 708-711.	21.4	445
69	Animal models of human type 1 diabetes. Nature Immunology, 2009, 10, 129-132.	14.5	100
70	H5N1 strain-specific Hemagglutinin CD4+ T cell epitopes restricted by HLA DR4. Vaccine, 2009, 27, 3862-3869.	3.8	7
71	Mucosal matters. Nature Reviews Immunology, 2008, 8, 409-409.	22.7	3
72	A nexus of science and clinical immunology: The Federation of Clinical Immunology Societies and the FOCIS Centers of Excellence. Clinical Immunology, 2008, 127, 119-120.	3.2	1

#	Article	IF	CITATIONS
73	Recurrence of autoreactive antigen-specific CD4+ T cells in autoimmune diabetes after pancreas transplantation. Clinical Immunology, 2008, 128, 23-30.	3.2	75
74	Characterization of effector functions of human peptide-specific CD4+ T-cell clones for an intracellular pathogen. Human Immunology, 2008, 69, 475-483.	2.4	14
75	Human homologues of a Borrelia T cell epitope associated with antibiotic-refractory Lyme arthritis. Molecular Immunology, 2008, 45, 180-189.	2.2	33
76	Searching for borrelial T cell epitopes associated with antibiotic-refractory Lyme arthritis. Molecular Immunology, 2008, 45, 2323-2332.	2.2	32
77	Autoreactive human T-cell receptor initiates insulitis and impaired glucose tolerance in HLA DR4 transgenic mice. Journal of Autoimmunity, 2008, 30, 197-206.	6.5	26
78	Decline in the Frequencies ofBorrelia burgdorferiOspA161–175-Specific T Cells after Antibiotic Therapy in HLA-DRB1*0401-Positive Patients with Antibiotic-Responsive or Antibiotic-Refractory Lyme Arthritis. Journal of Immunology, 2007, 179, 6336-6342.	0.8	28
79	Cutting Edge: High Molecular Weight Hyaluronan Promotes the Suppressive Effects of CD4+CD25+ Regulatory T Cells. Journal of Immunology, 2007, 179, 744-747.	0.8	156
80	Alteration of Cellular and Humoral Immunity by Mutant p53 Protein and Processed Mutant Peptide in Head and Neck Cancer. Clinical Cancer Research, 2007, 13, 7199-7206.	7.0	27
81	Antigen-Specific CD4 + T Cells Recognize Epitopes of Protective Antigen following Vaccination with an Anthrax Vaccine. Infection and Immunity, 2007, 75, 1852-1860.	2.2	27
82	Protective Versus Aggressive T Cell Responses to the Major Proinsulin73–90 Epitope in Beta-Islet Cell Autoimmunity. Clinical Immunology, 2007, 123, S27.	3.2	0
83	Evidence for an Increase in the Functional Avidity of the GAD-reactive CD4+ T Cell Population Prior to Diabetes Onset. Clinical Immunology, 2007, 123, S67.	3.2	Ο
84	Autoreactive T Cells in a Partially Humanized Murine Model of T1D. Annals of the New York Academy of Sciences, 2007, 1103, 69-76.	3.8	5
85	Su.20. Analysis of the Cd4 Effector T-Cell Response to Regulation in Diabetes Mellitus. Clinical Immunology, 2006, 119, S166.	3.2	Ο
86	Major Histocompatibility Complex and Autoimmunity. , 2006, , 47-58.		2
87	OR.45. Induction of Autoantigen-Specific Cd4+Cd25+ Regulatory T ells In Vitro. Clinical Immunology, 2006, 119, S20-S21.	3.2	Ο
88	Su.36. Gad-Reactive, Effector Memory Cd4+ T-Cells Cultured from Type 1 Diabetic Patients Express Increased Levels of the Voltage-Gated Potassium Channel Kv1.3: a Potential Therapeutic Target. Clinical Immunology, 2006, 119, S172.	3.2	0
89	Age-dependent loss of tolerance to an immunodominant epitope of glutamic acid decarboxylase in diabetic-prone RIP-B7/DR4 mice. Clinical Immunology, 2006, 121, 294-304.	3.2	14
90	A realâ€ŧime PCR approach for rapid high resolution subtyping of HLAâ€ÐRB1*04. Journal of Immunological Methods, 2006, 317, 64-70.	1.4	23

#	Article	IF	CITATIONS
91	Association of tumor necrosis factor α polymorphism, but not the shared epitope, with increased radiographic progression in a seropositive rheumatoid arthritis inception cohort. Arthritis and Rheumatism, 2006, 54, 1105-1116.	6.7	49
92	Identification of Novel HLA-A*0201-Restricted Epitopes in Recent-Onset Type 1 Diabetic Subjects and Antibody-Positive Relatives. Diabetes, 2006, 55, 3061-3067.	0.6	83
93	DRB1*0401-restricted human T cell clone specific for the major proinsulin73-90 epitope expresses a down-regulatory T helper 2 phenotype. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 11683-11688.	7.1	40
94	Kv1.3 channels are a therapeutic target for T cell-mediated autoimmune diseases. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 17414-17419.	7.1	470
95	Antibiotic-refractory Lyme arthritis is associated with HLA-DR molecules that bind a Borrelia burgdorferi peptide. Journal of Experimental Medicine, 2006, 203, 961-971.	8.5	187
96	Analysis of T-Cell Assays to Measure Autoimmune Responses in Subjects With Type 1 Diabetes. Diabetes, 2006, 55, 2588-2594.	0.6	91
97	Allelic Variation in Key Peptide-Binding Pockets Discriminates between Closely Related Diabetes-Protective and Diabetes-Susceptible <i>HLA-DQB1*06</i> Alleles. Journal of Immunology, 2006, 176, 1988-1998.	0.8	47
98	Recognition of HLA Class I-Restricted Â-Cell Epitopes in Type 1 Diabetes. Diabetes, 2006, 55, 3068-3074.	0.6	95
99	Targeting T Lymphocytes for Immune Monitoring and Intervention in Autoimmune Diabetes. American Journal of Therapeutics, 2005, 12, 534-550.	0.9	24
100	Functional avidity directs T-cell fate in autoreactive CD4+ T cells. Blood, 2005, 106, 2798-2805.	1.4	59
101	Tetramer Analysis of Human Autoreactive CD4â€Positive T Cells. Advances in Immunology, 2005, 88, 51-71.	2.2	15
102	<i>De novo</i> generation of antigen-specific CD4 <sup>+</sup> CD25 <sup>+</sup> regulatory T cells from human CD4 <sup>+</sup> CD25 <sup>–</sup> cells. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 4103-4108.	7.1	266
103	The insulin A-chain epitope recognized by human T cells is posttranslationally modified. Journal of Experimental Medicine, 2005, 202, 1191-1197.	8.5	201
104	GAD65- and proinsulin-specific CD4+ T-cells detected by MHC class II tetramers in peripheral blood of type 1 diabetes patients and at-risk subjects. Journal of Autoimmunity, 2005, 25, 235-243.	6.5	82
105	Extensive Replicative Capacity of Human Central Memory T Cells. Journal of Immunology, 2004, 172, 6675-6683.	0.8	46
106	Characterization of a <i>Mycobacterium tuberculosis</i> Peptide That Is Recognized by Human CD4+ and CD8+ T Cells in the Context of Multiple HLA Alleles. Journal of Immunology, 2004, 173, 1966-1977.	0.8	82
107	GAD65-Specific CD4+ T-Cells with High Antigen Avidity Are Prevalent in Peripheral Blood of Patients With Type 1 Diabetes. Diabetes, 2004, 53, 1987-1994.	0.6	100
108	Differential Recognition and Activation Thresholds in Human Autoreactive GAD-Specific T-Cells. Diabetes, 2004, 53, 971-977.	0.6	44

#	Article	IF	CITATIONS
109	Interaction betweenRANKL andHLA-DRB1 genotypes may contribute to younger age at onset of seropositive rheumatoid arthritis in an inception cohort. Arthritis and Rheumatism, 2004, 50, 3093-3103.	6.7	42
110	Inhibition of altered peptide ligand-mediated antagonism of human GAD65-responsive CD4+ T?cells by non-antagonizable T?cells. European Journal of Immunology, 2004, 34, 3337-3345.	2.9	13
111	MHC Class II tetramers and the pursuit of antigen-specific T cells: define, deviate, delete. Clinical Immunology, 2004, 110, 232-242.	3.2	59
112	Detection of CD4+Autoreactive T Cells in T1D Using HLA Class II Tetramers. Annals of the New York Academy of Sciences, 2003, 1005, 82-87.	3.8	44
113	Low-avidity recognition by CD4+ T cells directed to self-antigens. European Journal of Immunology, 2003, 33, 1409-1417.	2.9	62
114	Binding of outer surface protein A and human lymphocyte function-associated antigen 1 peptides to HLA-DR molecules associated with antibiotic treatment-resistant Lyme arthritis. Arthritis and Rheumatism, 2003, 48, 534-540.	6.7	94
115	How important is GAD in the etiology of spontaneous disease in human and murine type 1 diabetes?. Journal of Autoimmunity, 2003, 20, 193-194.	6.5	8
116	Conversations with GAD. Journal of Autoimmunity, 2003, 20, 195-198.	6.5	7
117	MHC multimers: expanding the clinical toolkit. Clinical Immunology, 2003, 106, 1-4.	3.2	14
118	HLA tetramer-based artificial antigen-presenting cells for stimulation of CD4+ T cells. Clinical Immunology, 2003, 106, 16-22.	3.2	70
119	Differential Antigen Sensitivity and Costimulatory Requirements in Human Th1 and Th2 Antigen-Specific CD4+ Cells with Similar TCR Avidity. Journal of Immunology, 2003, 170, 1218-1223.	0.8	27
120	Successful Prospective Prediction of Type 1 Diabetes in Schoolchildren Through Multiple Defined Autoantibodies: An 8-year follow-up of the Washington State Diabetes Prediction Study. Diabetes Care, 2002, 25, 505-511.	8.6	151
121	Detection of GAD65-Specific T-Cells by Major Histocompatibility Complex Class II Tetramers in Type 1 Diabetic Patients and At-Risk Subjects. Diabetes, 2002, 51, 1375-1382.	0.6	189
122	Genetics of rheumatoid arthritis: is there a scientific explanation for the human leukocyte antigen association?. Current Opinion in Rheumatology, 2002, 14, 254-259.	4.3	37
123	Defining antigen-specific responses with human MHC class II tetramers. Journal of Allergy and Clinical Immunology, 2002, 110, 199-208.	2.9	23
124	Mutational analysis of critical residues determining antigen presentation and activation of HLA-DQ0602 restricted T-cell clones. Human Immunology, 2002, 63, 185-193.	2.4	20
125	Transcript array analysis in rheumatology. Rheumatic Disease Clinics of North America, 2002, 28, 151-176.	1.9	1
126	Differential presentation of group A streptococcal superantigens by HLA class II DQ and DR alleles. European Journal of Immunology, 2002, 32, 2570-2577.	2.9	57

#	Article	IF	CITATIONS
127	HLA class II tetramers: Tools for direct analysis of antigen-specific CD4+ T cells. Arthritis and Rheumatism, 2002, 46, 5-12.	6.7	69
128	Modulation of T cell response to hGAD65 peptide epitopes. Tissue Antigens, 2002, 59, 101-112.	1.0	21
129	Therapy of autoimmune diseases: clinical trials and new biologics. Current Opinion in Immunology, 2002, 14, 812-815.	5.5	29
130	Class II peptide multimers: promise for type 1A diabetes?. Nature Immunology, 2002, 3, 344-345.	14.5	4
131	THE ROLE OF THE DR4 SHARED EPITOPE IN SELECTION AND COMMITMENT OF AUTOREACTIVE T CELLS IN RHEUMATOID ARTHRITIS. Rheumatic Disease Clinics of North America, 2001, 27, 305-315.	1.9	28
132	Rapid epitope identification from complex class-II-restricted T-cell antigens. Trends in Immunology, 2001, 22, 583-588.	6.8	52
133	T Cell Selection and Differential Activation on Structurally Related HLA-DR4 Ligands. Journal of Immunology, 2001, 167, 3250-3256.	0.8	20
134	Low-Dose Streptozotocin Induces Sustained Hyperglycemia in Macaca nemestrina. Autoimmunity, 2001, 33, 103-114.	2.6	13
135	Activated human epitope-specific T cells identified by class II tetramers reside within a CD4high, proliferating subset. International Immunology, 2001, 13, 799-806.	4.0	62
136	Complexity of Human Immune Response Profiles for CD4 <sup>+</sup> T Cell Epitopes from the Diabetes Autoantigen GAD65. Autoimmunity, 2001, 34, 231-240.	2.6	6
137	Tetramer-Guided Epitope Mapping: Rapid Identification and Characterization of Immunodominant CD4+ T Cell Epitopes from Complex Antigens. Journal of Immunology, 2001, 166, 6665-6670.	0.8	135
138	Antigen recognition. Current Opinion in Immunology, 2000, 12, 77-79.	5.5	4
139	β57-Asp Plays an Essential Role in the Unique SDS Stability of HLA-DQA1*0102/DQB1*0602 αβ Protein Dimer, the Class II MHC Allele Associated with Protection from Insulin-Dependent Diabetes Mellitus. Journal of Immunology, 2000, 165, 3232-3238.	0.8	37
140	Distinct T Cell Interactions with HLA Class II Tetramers Characterize a Spectrum of TCR Affinities in the Human Antigen-Specific T Cell Response. Journal of Immunology, 2000, 165, 6994-6998.	0.8	61
141	HLA-DQ Tetramers Identify Epitope-Specific T Cells in Peripheral Blood of Herpes Simplex Virus Type 2-Infected Individuals: Direct Detection of Immunodominant Antigen-Responsive Cells. Journal of Immunology, 2000, 164, 4244-4249.	0.8	118
142	Increased frequency of HLA class II alleles DRB1â^—0301 and DQB1â^—0201 in Lambert-Eaton myasthenic syndrome without associated cancer. Human Immunology, 2000, 61, 828-833.	2.4	29
143	Gene therapy in the treatment of autoimmune diseases. Journal of Clinical Investigation, 2000, 106, 181-183.	8.2	30

#	Article	IF	CITATIONS
145	HLA and Rheumatoid Arthritis. , 2000, , 181-185.		2
146	Radioimmunoassay for Glutamic Acid Decarboxylase-65. Diabetes Technology and Therapeutics, 1999, 1, 13-20.	4.4	13
147	Allelic variation in transcription modulates MHC class II expression and function. Microbes and Infection, 1999, 1, 919-927.	1.9	19
148	MHC-peptide ligand interactions establish a functional threshold for antigen-specific T cell recognition. Human Immunology, 1999, 60, 608-618.	2.4	13
149	Peptide binding affinity and pH variation establish functional thresholds for activation of HLA-DQ-restricted T cell recognition. Human Immunology, 1999, 60, 619-626.	2.4	3
150	MHC class II tetramers identify peptide-specific human CD4+ T cells proliferating in response to influenza A antigen. Journal of Clinical Investigation, 1999, 104, R63-R67.	8.2	342
151	Modulation of Peptide-Dependent Allospecific Epitopes on HLA-DR4 Molecules by HLA-DM. Human Immunology, 1998, 59, 77-86.	2.4	10
152	Promiscuous T-Cell Recognition of a Rubella Capsid Protein Epitope Restricted by DRB1â^—0403 and DRB1â^—0901 Molecules Sharing an HLA DR Supertype. Human Immunology, 1998, 59, 149-157.	2.4	16
153	Major Histocompatibility Complex-Directed Susceptibility to Rheumatoid Arthritis. Advances in Immunology, 1998, 68, 315-332.	2.2	89
154	High Affinity Presentation of an Autoantigenic Peptide in Type I Diabetes by an HLA Class II Protein Encoded in a Haplotype Protecting From Disease. Journal of Autoimmunity, 1997, 10, 375-386.	6.5	57
155	Recognition of contiguous allele-specific peptide elements in the Rubella virus E1 envelope protein. Vaccine, 1997, 15, 648-652.	3.8	7
156	Role of HLA Susceptibility in Predisposing to Insulin-Dependent Diabetes mellitus. Frontiers of Hormone Research, 1997, 22, 46-67.	1.0	2
157	Use of T cell receptor/HLA-DRB1*04 molecular modeling to predict site-specific interactions for the DR shared epitope associated with rheumatoid arthritis. Arthritis and Rheumatism, 1997, 40, 1316-1326.	6.7	3
158	Use of T cell receptor/HLA-DRB1*04 molecular modeling to predict site-specific interactions for the DR shared epitope associated with rheumatoid arthritis. Arthritis and Rheumatism, 1997, 40, 1316-1326.	6.7	26
159	Allele-specific transcriptional regulation of HLA-DQB1 genes. Human Immunology, 1996, 47, 12.	2.4	1
160	Interactions of peptide side chains with structurally complementary pockets in DQ molecules are critical for allele-specific peptide binding and T cell reactivity. Human Immunology, 1996, 47, 17.	2.4	1
161	Allelic variants of MHC class II Molecules can ACT as partial agonists of antigen-specific T cell responses. Human Immunology, 1996, 47, 149.	2.4	3
162	A Structural Model for TCR Recognition of the HLA Class II Shared Epitope Sequence Implicated in Susceptibility to Rheumatoid Arthritis. Journal of Autoimmunity, 1996, 9, 287-293.	6.5	47

#	Article	IF	CITATIONS
163	Characterization of a Novel Reverse-orientation Model for a Peptide/MHC Complex Putatively Associated with Type I Diabetes Mellitus. Journal of Molecular Modeling, 1996, 2, 205-216.	1.8	5
164	Recognition of altered self major histocompatibility complex molecules modulated by specific peptide interactions. European Journal of Immunology, 1996, 26, 949-952.	2.9	15
165	Characterization of the HLA-restrictive elements of a rubella virus-specific cytotoxic T cell clone: influence of HLA-DR4β chain residue 74 polymorphism on antigenic peptide-T cell interaction. International Immunology, 1996, 8, 1577-1586.	4.0	16
166	Polyglot and polymorphism. An HLA update. Arthritis and Rheumatism, 1995, 38, 1715-1721.	6.7	16
167	Clutamic acid decarboxylase and other autoantigens in IDDM. Current Opinion in Immunology, 1995, 7, 825-830.	5.5	26
168	Differential Transcription Elements Direct Expression of HLA-DQ Genes. Clinical Immunology and Immunopathology, 1995, 74, 119-126.	2.0	12
169	Genetic and Immunological Markers of Insulin Dependent Diabetes in Black Americans. Autoimmunity, 1995, 22, 27-32.	2.6	19
170	CLASS II ANTIGENS AND DISEASE SUSCEPTIBILITY. Annual Review of Medicine, 1995, 46, 17-25.	12.2	54
171	Ultrastructural allelic variation in HLA-DQB1 promoter elements. Human Immunology, 1995, 43, 251-258.	2.4	14
172	Analysis of overlapping T- and B-Cell antigenic sites on rubella virus E1 envelope protein influence of HLA-DR4 polymorphism on T-cell clonal recognition. Human Immunology, 1994, 39, 177-187.	2.4	19
173	The Major Histocompatibility Complex. BioDrugs, 1994, 2, 79-83.	0.7	2
174	Locus- and allele-specific DNA-protein interactions in the HLA-DQB1 X box. Immunologic Research, 1993, 12, 317-329.	2.9	9
175	Autoreactive T cells from a type I diabetic recognize multiple class II products. Human Immunology, 1993, 36, 219-226.	2.4	8
176	Allele-Specific Dna-Protein Interactions Associated with the X-Box Regulatory Region of the DQB1*0302 Gene. Autoimmunity, 1993, 15, 8-11.	2.6	4
177	Analysis of differential HLA-DQB expression in autologous B cell lines. Journal of Leukocyte Biology, 1993, 53, 697-706.	3.3	10
178	SELECTIVE T-CELL-RECEPTOR GENE USAGE IN ALLORECOGNITION AND GRAFT-VERSUS-HOST DISEASE. Transplantation, 1993, 55, 1167-1175.	1.0	17
179	T-cell receptor Vβ selectivity in T-cell clones alloreactive to HLA-Dw14. Human Immunology, 1992, 33, 57-64.	2.4	18
180	Molecular autoimmunity. Trends in Immunology, 1992, 13, 332.	7.5	0

#	Article	IF	Citations
181	Allorecognition of HLAâ€ĐQw8 molecules: Influence of single amino acid substitutions. Tissue Antigens, 1992, 39, 95-98.	1.0	3
182	Molecular Genetics of Autoimmunity. , 1992, , 127-152.		4
183	PREDICTION OF SUSCEPTIBILITY TO RHEUMATOID ARTHRITIS BY HUMAN LEUKOCYTE ANTIGEN GENOTYPING. Rheumatic Disease Clinics of North America, 1992, 18, 785-792.	1.9	79
184	DISEASE MARKERS AND NEW THERAPEUTICS. Rheumatic Disease Clinics of North America, 1992, 18, 719-727.	1.9	1
185	T-cell clones identify three distinct epitopes associated with HLA-Dw14. Human Immunology, 1991, 32, 229-233.	2.4	6
186	Structural and functional constraints on HLA class II dimers implicated in susceptibility to insulin dependent diabetes mellitus. Bailliere's Clinical Endocrinology and Metabolism, 1991, 5, 375-393.	1.0	13
187	Alloreactive T-cell clones identify multiple HLA-DQw3 variants. Human Immunology, 1991, 30, 32-40.	2.4	6
188	Investigating the HLA component in rheumatoid arthritis: An additive (dominant) mode of inheritance is rejected, a recessive mode is preferred. Genetic Epidemiology, 1991, 8, 153-175.	1.3	93
189	Association of HLA–Dw16 with rheumatoid arthritis in Yakima Indians. Further evidence for the "shared epitope―hypothesis. Arthritis and Rheumatism, 1991, 34, 43-47.	6.7	161
190	Is DQB2 Functional Among Nonhuman Primates?. , 1991, , 221-229.		2
191	A Unified Hypothesis for the Complex Genetics of HLA Associations With IDDM. Diabetes, 1990, 39, 1153-1157.	0.6	183
192	HLA and type I diabetes. Trends in Immunology, 1990, 11, 314-315.	7.5	26
193	Molecular biology of immune diseases and immune response. Trends in Immunology, 1990, 11, 150-151.	7.5	1
194	Mutagenesis and Expression of Putative Class II Susceptibility Genes: a "Reverse Immunogenetics― Approach to Analysis of HLA and Disease. Autoimmunity, 1990, 7, 189-199.	2.6	2
195	Further DNA sequence microheterogeneity of the HLA-DR4/Dw13 haplotype group: Importance of amino acid position 86 of the DRβ1 chain for T-cell recognition. Human Immunology, 1990, 27, 378-389.	2.4	30
196	The HLA genetic contribution to rheumatoid arthritis. Clinical Immunology Newsletter, 1990, 10, 127-131.	0.1	0
197	HLA-DQ and Diabetes Mellitus: A Genetic and Structural Paradigm for Models of Disease Susceptibility. , 1990, , 251-262.		0
198	The Effects of Variations in Human Immune-Response Genes. New England Journal of Medicine, 1989, 321, 751-752.	27.0	19

#	Article	IF	CITATIONS
199	Structural variation among major histocompatibility complex class-II genes which predispose to autoimmunity. Immunologic Research, 1989, 8, 16-38.	2.9	14
200	HLA class II typing using oligonucleotide probes. Genetic Epidemiology, 1989, 6, 27-30.	1.3	4
201	HLA DQβ3.2 identifies subtypes of DR4 + haplotypes permissive for IDDM. Genetic Epidemiology, 1989, 6, 149-154.	1.3	13
202	HLA Genes associated with rheumatoid Arthritis. Identification of susceptibility alleles using specific oligonucleotide probes. Arthritis and Rheumatism, 1989, 32, 15-21.	6.7	329
203	Sequence analysis of HLA class II domains: characterization of the DQw3 family of DQB genes. Immunogenetics, 1989, 29, 186-190.	2.4	17
204	Determinants of genetic susceptibility in HLA-associated autoimmune disease. Clinical Immunology and Immunopathology, 1989, 53, S53-S62.	2.0	15
205	HLA-DR4-Associated Disease: Oligonucleotide Probes Identify Specific Class II Susceptibility Genes in Type I Diabetes and Rheumatoid Arthritis. , 1989, , 404-406.		1
206	DQw3 (DQw7, DQw8, DQw9): 2-D Gel Patterns. , 1989, , 412-415.		0
207	Transfer and Expression of an IDDM Susceptibility Gene into Lymphoblastoid Cell Lines by Retroviral Vectors. , 1989, , 406-408.		Ο
208	Evolution of DQw2-Related Haplotypes. , 1989, , 283-285.		0
209	Structural and genetic features of human leukocytic antigen class II elements associated with rheumatoid arthritis. American Journal of Medicine, 1988, 85, 12-13.	1.5	6
210	DQw3 variants defined by cloned alloreactive T cells. Human Immunology, 1988, 21, 63-73.	2.4	13
211	Molecular analysis of DQÎ23.1 genes. Human Immunology, 1988, 21, 183-192.	2.4	22
212	SPECIFIC ALLELIC VARIATION AMONG LINKED HLA CLASS II GENES. Transplantation, 1987, 44, 831-835.	1.0	12
213	Functional polymorphisms among HLA-DR4+ DR beta chains associated with limited peptide diversity. Molecular Immunology, 1987, 24, 471-477.	2.2	11
214	Anti-idiotypic antibodies and the induction of specific tumor immunity. Cancer and Metastasis Reviews, 1987, 6, 489-502.	5.9	20
215	The molecular basis for HLA class II associations with rheumatoid arthritis. Journal of Clinical Immunology, 1987, 7, 1-7.	3.8	145
216	HLA Class II Variants: Structural Studies and Disease Associations. Annals of the New York Academy of Sciences, 1986, 475, 1-11.	3.8	10

#	Article	IF	CITATIONS
217	A deletion mutant defines DQβ variants within DR4 positive DQw3 positive haplotypes. Human Immunology, 1986, 17, 87-93.	2.4	7
218	DNA restriction fragment length polymorphism of HLA-DR2: Correlation with HLA-DR2-associated functions. Journal of Neuroimmunology, 1986, 12, 195-203.	2.3	11
219	Immunogenetics of Disease Susceptibility: New Perspectives in HLA. Pathology and Immunopathology Research, 1986, 5, 37-46.	0.8	4
220	Tryptic peptide mapping identifies structural heterogeneity among six variants of HLA-B27. Immunogenetics, 1986, 23, 409-412.	2.4	11
221	Six variants of HLA-1327 identified by isoelectric focusing. Immunogenetics, 1986, 23, 24-29.	2.4	90
222	Exon-specific oligonucleotide probes localize HLA-DQ ? allelic polymorphisms. Immunogenetics, 1986, 24, 251-258.	2.4	41
223	ldiotypic interactions in immune responses to tumor-associated antigens. Biochimica Et Biophysica Acta: Reviews on Cancer, 1986, 865, 127-139.	7.4	9
224	HLAâ€ÐQ heterogeneity among HLAâ€ÐRw11(5) haplotypes. Tissue Antigens, 1986, 28, 278-287.	1.0	1
225	Electrophoretic variation between class II molecules expressed on HLA-DRw8 homozygous typing cells reveals multiple distinct haplotypes. Immunogenetics, 1985, 21, 49-60.	2.4	27
226	Biochemical definition of distinct HLA haplotypes associated with juvenile rheumatoid arthritis. Clinical Immunology Newsletter, 1985, 6, 5-7.	0.1	0
227	Human Immune Response Genes. , 1985, , 3-19.		2
228	Multiple Ia-like molecules characterize HLA-DR2-associated haplotypes which differ in HLA-D. Human Immunology, 1984, 10, 143-151.	2.4	52
229	HLA-DR antigens on lymphoid cells differ from those on myeloid cells. Nature, 1983, 305, 541-543.	27.8	41
230	Enhanced detection of immunoglobulin binding by a modified ELISA. Journal of Immunological Methods, 1983, 60, 47-52.	1.4	7